Features of peripheral neuropathy
| . | Once-weekly bortezomib (n = 369) . | Twice-weekly bortezomib (n = 134) . | P . |
|---|---|---|---|
| Cumulative proportion of patients with PN at 18 mo (95% CI) | |||
| Any grade | 0.40 (0.35-0.45) | 0.72 (0.64-0.79) | < .001 |
| Sensory neuropathy | 0.27 (0.22-0.32) | 0.46 (0.37-0.54) | < .001 |
| Neuralgia | 0.08 (0.05-0.10) | 0.13 (0.07-0.19) | .058 |
| Sensory and neuralgia | 0.06 (0.03-0.08) | 0.13 (0.07-0.19) | .008 |
| Grade 3/4 | 0.09 (0.06-0.12) | 0.36 (0.26-0.45) | < .001 |
| Sensory neuropathy | 0.04 (0.01-0.06) | 0.21 (0.13-0.29) | < .001 |
| Neuralgia | 0.03 (0.01-0.05) | 0.05 (0.01-0.10) | .234 |
| Sensory and neuralgia | 0.03 (0.01-0.04) | 0.09 (0.04-0.15) | .006 |
| Bortezomib dose modification caused by PN | |||
| Dose reduction, n (%) | 63 (17) | 55 (41) | < .001 |
| Drug discontinuation, n (%) | 20 (5) | 20 (15) | < .001 |
| Median time to dose reduction, mo (IQR) | 3.8 (1.8-5.9) | 2.8 (1.6-4.8) | .08 |
| Median time to discontinuation, mo (IQR) | 7.6 (5.7-9.6) | 7.0 (4.7-11.1) | .91 |
| Outcome of grade 2-4 PN | n = 77 | n = 73 | |
| Resolution, n (%) | 26 (34) | 29 (40) | .74 |
| Improvement, n (%) | 23 (30) | 19 (26) | |
| Persistence, n (%) | 28 (36) | 25 (34) | |
| Median time to recovery, mo (IQR) | 2.3 (1.1-4.0) | 3.2 (2.1-4.8) | .005 |
| . | Once-weekly bortezomib (n = 369) . | Twice-weekly bortezomib (n = 134) . | P . |
|---|---|---|---|
| Cumulative proportion of patients with PN at 18 mo (95% CI) | |||
| Any grade | 0.40 (0.35-0.45) | 0.72 (0.64-0.79) | < .001 |
| Sensory neuropathy | 0.27 (0.22-0.32) | 0.46 (0.37-0.54) | < .001 |
| Neuralgia | 0.08 (0.05-0.10) | 0.13 (0.07-0.19) | .058 |
| Sensory and neuralgia | 0.06 (0.03-0.08) | 0.13 (0.07-0.19) | .008 |
| Grade 3/4 | 0.09 (0.06-0.12) | 0.36 (0.26-0.45) | < .001 |
| Sensory neuropathy | 0.04 (0.01-0.06) | 0.21 (0.13-0.29) | < .001 |
| Neuralgia | 0.03 (0.01-0.05) | 0.05 (0.01-0.10) | .234 |
| Sensory and neuralgia | 0.03 (0.01-0.04) | 0.09 (0.04-0.15) | .006 |
| Bortezomib dose modification caused by PN | |||
| Dose reduction, n (%) | 63 (17) | 55 (41) | < .001 |
| Drug discontinuation, n (%) | 20 (5) | 20 (15) | < .001 |
| Median time to dose reduction, mo (IQR) | 3.8 (1.8-5.9) | 2.8 (1.6-4.8) | .08 |
| Median time to discontinuation, mo (IQR) | 7.6 (5.7-9.6) | 7.0 (4.7-11.1) | .91 |
| Outcome of grade 2-4 PN | n = 77 | n = 73 | |
| Resolution, n (%) | 26 (34) | 29 (40) | .74 |
| Improvement, n (%) | 23 (30) | 19 (26) | |
| Persistence, n (%) | 28 (36) | 25 (34) | |
| Median time to recovery, mo (IQR) | 2.3 (1.1-4.0) | 3.2 (2.1-4.8) | .005 |
CI indicates confidence interval; IQR, interquartile range; and PN, peripheral neuropathy.